0009K0.KQ Overview

Company Profile

Aimed Bio Inc. develops therapeutic solutions for patients with brain diseases, including neuro-oncological and degenerative diseases. Its multidisciplinary platform offers antibody-drug conjugates, blood-brain barrier penetration, brain immune modulation, and patient-derived models (PDC/PDX). Aimed Bio Inc. was founded in 2018 and is based in Seoul, South Korea.

Related stocks

096530.KQ

096530.KQ • South Korea

38,150 KRW

1.3B USD 1Y +51.4%

145020.KQ

145020.KQ • South Korea

182,800 KRW

1.47B USD 1Y -36%

347850.KQ

347850.KQ • South Korea

42,850 KRW

1.47B USD 1Y -14.8%

226950.KQ

226950.KQ • South Korea

117,300 KRW

1.84B USD 1Y +27.9%

310210.KQ

310210.KQ • South Korea

138,400 KRW

1.9B USD 1Y -19.1%

298380.KQ

298380.KQ • South Korea

48,000 KRW

2.01B USD 1Y -49.9%

141080.KQ

141080.KQ • South Korea

73,300 KRW

2.02B USD 1Y -51.9%

302440.KS

302440.KS • South Korea

36,750 KRW

2.15B USD 1Y -22.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Website

https://www.aimedbio.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

3Y Volatility

-

Max Drawdown (3Y)

-

Sharpe Ratio (3Y)

-

Size Class

Mega Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.